Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

XLO

+ Watchlist+ Portfolio

Xilio Therapeutics, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$7.55
52-Week Range
$6.47 – $11.20
Market Cap
$53.90M
P/E (TTM)
11.74
EPS (TTM)
0.65
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.74
PEG Ratio
—
Return on Equity
-38.21%
Return on Assets
-19.17%
Gross Margin
79.50%
Operating Margin
-74.87%
Profit Margin
-20.89%
Current Ratio
4.72
Debt/Equity
0.09
Total Debt
$5.96M
Free Cash Flow
$-30.25M
Revenue Growth
-47.60%
Earnings Growth
—
Enterprise Value
$-62.32M

Market Snapshot

About

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies. The company utilizes its proprietary platform to engineer cytokines and other immune-modulatory proteins that are activated in the tumor microenvironment. Xilio aims to improve the therapeutic index of cancer treatments while reducing systemic toxicity.